Navigation Links
Novel Biological Pacemaker Under Construction for Weak Hearts

Johns Hopkins scientists have developed a natural or rather biological pacemaker by fusing connective tissue cells of guinea pigs with heart muscle cells. The newly developed pacemaker can fire on it’s own and regulate the rhythm // of the heart in a more physiological way.

Two sets of tiny electroactive 'pacing cells' (SA node) give rise to the heart’s normal rhythm by stimulating other cells to contract in certain sequences. Potentially fatal arrythmias occur when these pacing cells are damaged or die. Pacemaker implantation is lifesaving in groups of patient tolerant to the device.

The invention of the first external cardiac pacemaker by Canadian Researcher, John Hopps in 1950 is a milestone worth remembering in this regard. From what was known at that time, we have indeed come a long way in the development of the biological pacemaker.

The researchers successfully combined regular heart muscle cells having no pacing abilities with fibroblasts modified by a gene (HCN1) to help in the transmission of electrical signals. The fibroblasts were taken from the animals’ lungs. Following three minutes of cell fusion, the derived cell showed the desired activity of producing it’s own electric current. The cells behaved very similar to the natural cardiac pacemaker cells and were viable for 2 weeks.

Subsequently, the introduction of these cells into the ‘weakened’ animal hearts revealed successful incorporation into the heart muscle cells. Infact, the heart rate quadrupled to nearly half-normal levels. These cells retained the property of firing spontaneously, a hallmark of pacing cells normally found in the heart.

The disadvantages of the currently available electronic pacemaker include the necessity for periodic battery replacement, an implantation of a permanent tube (catheter) in the chest to ensure access to the pacemaker. The risk of infection is also much high due to the need for embedding diodes to carry ele ctric current inside the heart.

Other biopacemaker technologies use adenoviruses as part of gene therapy to carry pacing genes into the heart, or use combinations of gene- and stem cell therapies. This can cause arrythmias as the result of inflammation or uncontrolled cell growth. Moreover, guiding the stem cells into the target tissue is one of technical hurdles to be circumvented.

The biological pacemaker has numerous advantages over the conventional one in the sense it can serve as an ideal alternative in infection-prone patients or who are physically too weak to have a mechanical pacemaker implanted. Moreover, fibroblasts are found throughout the body, even in skin. These construction blocks are much easier to grow and handle in the lb.
'"/>




Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Novel Therapy for Chronic Problem
9. Blood Sugar Kept In Control By Novel Protein
10. Novel antibiotic dressing developed for improved wound healing
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and ... the ultimate weight loss and wellness program, at their world headquarters of Omni La ... immediate and long-term results to anyone seeking weight loss, personal development, a healthy lifestyle, ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... continuity to its innovative Unified Instance Manager architecture, meeting the needs of ... new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, provides ...
(Date:12/8/2016)... ... 08, 2016 , ... STATEN ISLAND, N.Y., Nov. 24, 2016 ... the highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) ... Dr. Daniel Messina. , Among the recognitions, the American College of Surgeons' (ACS) ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into law ... in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition ... to the study, medical payments per claim in California decreased 4 percent in 2013 ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Care Act. Dr. Botelho advocates for the mass media launching of story movements ... ongoing opportunities to share their unfortunate experiences; such a movement can generate the ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Henry Schein, Inc. (Nasdaq: ... care products and services to office-based dental, animal health and ... equity investment in Marrodent, one of Poland,s ... $32 million. This transaction was announced on August 30, 2016. ... Poland since 2014, and Marrodent marks ...
(Date:12/8/2016)... 2016 Research and Markets has announced the addition ... to their offering. ... The report provides separate comprehensive analytics for ... and Rest of World. Annual estimates and forecasts are ... is provided for these markets. Market data and analytics are derived from ...
(Date:12/7/2016)... -- "Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight" report by ... drug in clinical pipeline. Currently 5 biosimilar version of Lantus are commercially ... Kenya , Czech Republic , ... , Slovakia , United Kingdom ... patent on Lantus expired in 2014. Lantus is the brand name ...
Breaking Medicine Technology: